Gabatherabbreviated Form Of Gaba Therapeuticsfocuses On The Development Of Highly Potent And Selective Gabaa Receptor Modulators Targeting The Principal Inhibitory Neurotransmitter In The Mammalian Braingamma Aminobutyric Acidgaba Our Drug Development Candidates Are Small Molecular Weight Compounds Designed Through Proprietary Pharmacophore Modellingour Development Pipeline Includes Candidates Targeting The Gabaa Receptor In Both Preclinical And Clinical Development And We Aim To Produce Novel Pharmaceuticals Such As Antipsychoticsantidepressantsanxiolyticsanalgesics And Cognitive Enhancers To Treat Cns Diseases With High Unmet Need
